44 results about "Membrane glycoproteins" patented technology

The present disclosure belongs to the field of biotechnology, and specifically relates to a method for efficiently infecting human natural killer (NK) cells and other immune cells with a pseudovirus. Specifically, a viral transfection system provided in the present disclosure has an envelope plasmid with a protein having an X—Y—Z structure. The X is an extracellular (ex) structure of a gibbon ape leukemia virus (GALV) envelope glycoprotein, the Y is a transmembrane (TM) structure of the GALV envelope glycoprotein, and the Z is an intracellular segment portion of a murine virus gene.

The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of be soluble expression in an Escherichia coli expression system, and use thereof in preventing and / or treating varicella-zoster virus infections.

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The invention belongs to the technical field of biology, and particularly relates to sgRNA of a targeted ASCT2 gene and application of the sgRNA. Two efficient knockout targets are provided for the human ASCT2 gene, and knockout effect detection and identification show that the two sgRNAs can effectively knock out the ASCT2 gene on a 293T cell. The 293T cells without the ASCT2 gene are high in stability, formation of syncytial bodies induced by BaEV envelope glycoprotein can be remarkably inhibited, cell source impurities in lentivirus preparation liquid are greatly reduced, the titer of BaEV envelope lentivirus is increased by 5 times, and the method has practical application value.

The invention provides BaEV-G envelope glycoprotein, an optimization method of the BaEV-G envelope glycoprotein and an envelope plasmid, a packaging method and a kit which relate to the BaEV-G envelope glycoprotein, and particularly relates to the optimization method of the BaEV-G envelope glycoprotein, chimeric BaEV-G envelope glycoprotein, a lentivirus envelope plasmid, a pseudotyped packaging method of lentivirus and the kit. The BaEV-G envelope glycoprotein and the VSV-G envelope glycoprotein are chimeric to obtain the chimeric BaEV-G envelope glycoprotein, and the properties of lentivirus packaging efficiency, biological activity and the like can be effectively improved.

The high pathogenicity of the rift valley fever virus limits the research on the pathogenic mechanism and prevention, control and treatment products of the rift valley fever virus, the offspring replication-deficient virus particles are successfully saved through a reverse genetic manipulation technology, and the virus particles do not have the capacity of multiple rounds of infection on common cells; stable replication and passage can only be realized in a cell line for providing exogenous envelope glycoprotein; in addition, the virus particle carries an exogenous indication protein and can indicate cell infection. The Rift Valley fever virus-like particle provided by the invention can be used as a Rift Valley fever biosafety secondary laboratory research platform, the establishment of the virus particle greatly simplifies tedious procedures in the Rift Valley fever virus research process, and paves a way for screening of Rift Valley fever virus neutralizing antibodies, research and development of candidate vaccines and research of pathogenic mechanisms of the Rift Valley fever viruses.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

In aspects, the present disclosure provides an enveloped delivery vehicle (EDV), comprising, consisting of, consisting essentially of: (1) an envelope membrane; (2) at least one first recombinant viral membrane glycoprotein (VMG) incorporated into the envelope membrane comprising a fusion protein comprising (A) a fusogenic membrane glycoprotein (FMG) comprising a substantially intact FMG and (B) a first targeting molecule; and (3) at least one second recombinant VMG incorporated into the envelope membrane comprising a fusion protein comprising (A) a FMG comprising a substantially intact FMG and (B) a second targeting molecule; wherein the first targeting molecule and the second targeting molecule are not the same. In aspects, the present disclosure provides methods of generating EDVs described herein. In aspects, the present disclosure provides a method of improving the cell infection efficiency of an EDV as described herein. Additional aspects are as described herein.

Disclosed are a specific marker combination of mesenchymal stem cell-derived small extracellular vesicles and the use thereof. The characteristic marker combination comprises aminopeptidase N (CD13), integrin β-1 (CD29), membrane glycoprotein THY-1 (CD90), and markers CD9, CD63 and CD81. By using the characteristic marker combination of mesenchymal stem cell-derived small extracellular vesicles for nano-flow cytometry analysis at the single-vesicle level, mesenchymal stem cell-derived small extracellular vesicles can be identified. On the basis of the provided characteristic marker combination, specific modification and engineering on the basis of small extracellular vesicle membrane proteins can further be realized.

The present disclosure is directed to membraned vesicles comprising: (a) an envelope membrane; and (b) viral membrane glycoproteins (VMGs), each VMG optionally within a fusion protein; wherein at least one VMG is incorporated into the envelope membrane and is within a fusion protein comprising at least one affinity tag, wherein at least one VMG is incorporated into the envelope membrane and comprises a fusogenic membrane glycoprotein (FMG), and wherein at least one affinity tag is displayed at the outer surface of the envelope membrane, wherein the outer surface is opposite the lumen of the membraned vesicle; and methods of generating membraned vesicles.

The application provides a BaEV-G envelope glycoprotein, an optimization method thereof, and an envelope plasmid, a packaging method and a kit related to the envelope glyprotein, in particular, relates to an optimization method of a BaEV-G envelope glyprotein, a chimeric BaEV-G envelope glyprotein, a lentivirus envelope plasmid, a lentivirus pseudotyped packaging method and a kit. The BaEV-G envelope glyprotein is chimerized with the VSV-G envelope glyprotein to obtain the chimeric BaEV-G envelope glyprotein, so that the lentivirus packaging efficiency, biological activity and other performances can be effectively improved.

The application provides a virus envelope chimeric receptor and related biomaterials and applications thereof, and belongs to the technical field of molecular biology. Specifically disclosed is a virus envelope chimeric receptor, which comprises, in sequence, an antibody or antigen-binding fragment thereof, a hinge region, a transmembrane region and an intracellular region; the hinge region is selected from a hinge region composed of a hinge region of a CD8 molecule and a hinge region of a vesicular stomatitis virus envelope glycoprotein; the transmembrane region of the virus envelope chimeric receptor is selected from a transmembrane region of the vesicular stomatitis virus envelope glycoprotein; and the intracellular region of the virus envelope chimeric receptor is selected from an intracellular region of the vesicular stomatitis virus envelope glycoprotein. The virus envelope chimeric receptor is used for virus targeting, can improve the infection ability of viruses, reduces the infection rate of viruses on non-T cells to less than 5%, provides a safety guarantee for in-vivo CAR-T preparation, and can be used for industrial production.

The present invention relates to engineered SIRP alpha variants and methods of use thereof. Signal regulatory protein a (SIRPa) is a regulatory membrane glycoprotein of the SIRP family. The protein is mainly expressed by bone marrow cells and also expressed by stem cells or neurons. SIRPa is used as an inhibitory receptor and interacts with a widely expressed transmembrane protein CD47. The present disclosure relates to engineered SIRPa variants and methods of use thereof.

The invention discloses a canine distemper virus envelope glycoprotein chimeric recombinant Newcastle disease virus as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The CDV F extracellular region chimeric recombinant Newcastle disease virus rNDV-cF and the CDV H protein extracellular region chimeric recombinant Newcastle disease virus rNDV-cH are successfully constructed, the immunogenicity of the recombinant viruses is improved, the CDV F and the CDV H are better packaged to the surface of the NDV, and the recombinant viruses have good genetic stability. After the rNDV-cF and the rNDV-cH are inactivated, an adjuvant is supplemented for independent immunization or combined immunization of mice and dogs, the result shows that all immunization groups can induce the body to generate good humoral immune response, and the rNDV-cH inactivated vaccine and combined immunization have equivalent immune effect, and have good protective effect on dogs attacked by CDV virulent strains; and an important material basis is laid for research and development of novel canine distemper carrier vaccines.

The invention discloses application of a biomarker in preparation of a product for diagnosing abdominal aortic aneurysm, a kit and a use method, the biomarker has the advantages of high sensitivity, strong specificity and high accuracy, and the detection method is simple and rapid and has important significance in early screening of abdominal aortic aneurysm. The biomarker is any one of the following exosome proteins or a combination thereof: fibrinogen beta chain, fibronectin, lysosome related membrane glycoprotein 2 and histone H4.

A chimeric antigen receptor (CAR) comprises an extracellular antigen binding domain, wherein the extracellular antigen binding domain comprises a polypeptide that binds to an oncostatin-M receptor (OSMR), a leukemia inhibitory factor receptor (LIFR), a heterodimer of a transmembrane glycoprotein 130 (gp130) receptor and OSMR, and / or a heterodimer of a gp130 receptor and LIFR.

The present disclosure is directed to membraned vesicles comprising: (a) an envelope membrane; and (b) viral membrane glycoproteins (VMGs), each VMG optionally within a fusion protein; wherein at least one VMG is incorporated into the envelope membrane and is within a fusion protein comprising at least one affinity tag, wherein at least one VMG is incorporated into the envelope membrane and comprises a fusogenic membrane glycoprotein (FMG), and wherein at least one affinity tag is displayed at the outer surface of the envelope membrane, wherein the outer surface is opposite the lumen of the membraned vesicle; and methods of generating membraned vesicles.

A composition comprising a brain targeted exosome derived from mesenchymal stem cells for systemically delivering an agent to target cells or tissues in the central nervous system of a patient, wherein the exosome expresses blood brain barrier (BBB) crossing central nervous system (CNS) specific AAV synthetic capsid (CAP) peptide. A method is provided for genetically engineering exosomes comprising joining a selected functional AAV capsid domain specific peptide (CAP), and fusing said CAP to lysosome-associated membrane glycoprotein (Lanp2b) to form a CAP-Lam2b fusion protein, and expressing CAP-lamp2b fusion protein on the surface of a mesenchymal stem cell derived exosome.

Signal regulatory protein alpha (SIRPα) is a regulatory membrane glycoprotein from the SIRP family. It is expressed primarily by myeloid cells, but also by stem cells and neurons. SIRPα acts as an inhibitory receptor and interacts with the widely expressed transmembrane protein CD47. The present disclosure relates to engineered SIRPα variants and methods of use thereof. TIFF2025501430000013.tif168133

The present invention relates to an expression vector, an expression cassette or a pseudotyped viral vector particle comprising at least one nucleic acid encoding at least one Koala Retrovirus (KoRV) Envelope glycoprotein (Env), related nucleic acids, pseudotyped viral vector particles, mammalian packaging cell lines, transduced mammalian cells as well as related methods and uses.

SOLUTION: The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., Staphylococcus aureus growth) and treating bacterial infections (e.g., Staphylococcus aureus infections). The disclosure further relates to rifamycin analog compounds and antibodies for inhibiting bacterial growth and treating bacterial infections, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, as well as methods of use thereof.SELECTED DRAWING: None

The invention discloses a lentiviral vector with efficient transduction capability on T cells and application of the lentiviral vector. The lentiviral vector comprises a nucleic acid sequence for coding recombinant virus envelope glycoprotein, and the recombinant virus envelope glycoprotein has the following structure from the N end to the C end in sequence; wherein the element A is a protein element of wild type virus envelope glycoprotein, the element B is an auxiliary protein element, the auxiliary protein element specifically recognizes cell membrane surface protein, and the element C is a transmembrane structural domain and is a peptide bond or a peptide chain connector. The lentivirus obtained by packaging the lentivirus vector containing the recombinant virus envelope glycoprotein can transduce T lymphocytes with higher efficiency, introduces an exogenous gene into the T lymphocytes, and can be used as a vector in the preparation process of CAR-T cells, so that the production efficiency of the CAR-T cells is improved, and the yield of the CAR-T cells is increased.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

This invention provides a method for efficient multi-gene editing and CAR site-directed integration based on BaEV envelope glycoprotein truncated viral particles and its application in immune cell engineering. The invention provides an MLV-VLP system utilizing BaEV envelope glycoprotein truncated particles to achieve efficient CRISPR-Cas9 delivery without electroporation or the use of randomly integrating viruses. Combined with adeno-associated virus (AAV6) delivery of HDR templates, it enables efficient site-directed integration of CAR sequences at target sites (such as TRAC, PD1, and B2M) in primary human T cells and NK cells. The prepared CAR-T or CAR-NK cells exhibit excellent cell killing, proliferation, and low exhaustion characteristics in vitro, achieving 100% tumor clearance in an in vivo mouse model. It can simultaneously achieve multi-gene knockout with high efficiency, supporting large-scale allogeneic CAR-T and CAR-NK cell production.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The present disclosure reports that a calcium-dependent serine protease, complement component is (C1s) has been identified as a protease responsive for cleavage of exogenous polypeptides expressed in mammalian cell lines such as CHO cells. These CHO cell lines provide for increased yield of antigenically correct, uncleaved exogenous polypeptide as compared to unmodified CHO cells expressing the active C1s protease. C1s-deficient cell lines and methods for use of same for producing exogenous polypeptides, e.g., human immunodeficiency virus (HIV) envelope glycoprotein polypeptides, such as, gp120 or human Factor VIII are provided.

A chimeric antigen receptor (CAR) comprises an extracellular antigen-binding domain, which comprises a polypeptide that binds to oncostatin M receptor (OSMR), leukemia inhibitory factor receptor (LIFR), a heterodimer between transmembrane glycoprotein 130 (gp130) receptor and OSMR, and / or a heterodimer between gp130 receptor and LIFR.

The invention belongs to the technical field of nucleic acid vaccines, and particularly relates to a coding gene of Zaire Ebola virus envelope glycoprotein, a related mRNA (messenger ribonucleic acid) molecule and application thereof. The nucleotide sequence of the gene is shown as SEQ ID NO.1. The DNA vaccine is prepared from the gene. A transcription template DNA of the mRNA molecule is formed by sequentially connecting a 5 'UTR region, a gene as shown in SEQ ID NO.1, a 3' UTR region and a PolyA tail, and all uridine in the mRNA molecule is replaced by N1-methyl-pseudouridine-5 '-triphosphoric acid; the method comprises the following steps: encapsulating mRNA molecules in lipid nanoparticles to form an mRNA vaccine; the vaccine provided by the invention can induce generation of an antigen-specific IgG antibody and a cross-neutralizing antibody aiming at an EBOV Mayinga strain, and also can induce antigen-specific cellular immune response of an immune mouse, so that the vaccine provided by the invention has the potential of preventing the Ebola virus disease.

The invention belongs to the technical field of biology, and particularly discloses a Nipah virus infectious clone based on an alphavirus replicon and application of the Nipah virus infectious clone in preparation of attenuated vaccines. The infectious clone is obtained by further screening after an envelope glycoprotein for coding the Nipah virus is inserted on the basis of an alphavirus replicon vector. The virus-like vesicles rescued by utilizing the infectious clone disclosed by the invention can be continuously and autonomously replicated and amplified, are high in virion titer, stably express antigen protein, and have good safety, immunogenicity and immune protection efficacy, so that the virus-like vesicles can effectively resist challenge infection of wild type viruses, and can be used for preparing safe and effective attenuated vaccine strains.